Bottom line
TBXU vs CURE: the short answer
TBXU (Direxion Daily Biotech Top 5 Bull 2X ETF) and CURE (Direxion Daily Healthcare Bull 3X ETF) are quite different portfolios: only about 39% of their top holdings (by weight) are shared.
But CURE is far broader, holding 67 positions to 10 for TBXU, so beyond the top names it adds exposure TBXU doesn't have.
CURE is cheaper at 0.94% vs 0.98% — a difference of $4.00 a year per $10,000 invested.
Updated Nov 19, 2026
TBXU vs CURE side by side
| TBXU | CURE | |
|---|---|---|
| Type | ETF | ETF |
| Fund family | Direxion | Direxion |
| Category | Leveraged & Inverse | Leveraged & Inverse |
| Expense ratio | 0.98% | 0.94% |
| Annual cost per $10k | $98 | $94 |
| 10-yr cost on $10k (prospectus) | $5,645 | $1,155 |
| Max front load | None | None |
| 12b-1 fee | 0% | 0% |
| 1-yr return | — | +22.9% |
| 5-yr return (annualized) | — | +8.6% |
| 10-yr return (annualized) | — | +13.6% |
| Best quarter | — | +46.9% |
| Worst quarter | — | −45.8% |
| Net assets (fund) | $2.6M | $171.7M |
| Number of holdings | 10 | 67 |
| Portfolio turnover | 69% | 1% |
| Returns as of | — | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Holdings overlap
8 of TBXU's top 10 holdings also appear in CURE's top 25.
| Holding | TBXU | CURE |
|---|---|---|
| Goldman Financial | 29.36% | 7.51% |
| Dreyfus | 21.64% | 18.79% |
| Amgen Inc | 7.95% | 2.38% |
| Vertex Pharmaceuticals Inc | 7.84% | 1.39% |
| Gilead Sciences Inc | 7.58% | 1.85% |
| Goldman Sachs Liq Es Fd A | 6.23% | 8.19% |
| N/a | 2.83% | 1.12% |
| N/a | 0.62% | 1.12% |
Source: SEC Form N-PORT
TBXU top 10
- Goldman Financial — 29.36%
- Dreyfus — 21.64%
- Regeneron Pharmaceuticals Inc — 9.09%
- Amgen Inc — 7.95%
- Vertex Pharmaceuticals Inc — 7.84%
- Gilead Sciences Inc — 7.58%
- Argenx Se - Adr — 6.98%
- Goldman Sachs Liq Es Fd A — 6.23%
- N/a — 2.83%
- N/a — 0.62%
CURE top 10
- Dreyfus — 18.79%
- Eli Lilly & Company — 10.41%
- N/a — 8.28%
- Goldman Sachs Liq Es Fd A — 8.19%
- Goldman Financial — 7.51%
- Johnson & Johnson — 7.07%
- Abbvie Inc — 5.08%
- Unitedhealth Group Inc — 4.31%
- Merck & Company Inc — 3.68%
- N/a — 3.34%
FAQ
What is the difference between TBXU and CURE?
Which is cheaper, TBXU or CURE?
Should I own both TBXU and CURE?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.